Lantheus Holdings to Host First Quarter 2021 Earnings Conference Call and Webcast on May 4, 2021 at 8:00 a.m. Eastern Time
Lantheus Holdings, Inc. (NASDAQ: LNTH) has announced its upcoming conference call and webcast scheduled for May 4, 2021, at 8:00 a.m. ET, to discuss the financial and operational results for Q1 2021. Interested parties can join by dialing the provided numbers or through the company's website. Lantheus is known for its innovative imaging diagnostics and therapeutics, including products like DEFINITY® and TechneLite®. The company is headquartered in North Billerica, Massachusetts, with operations in multiple locations.
- Innovative product portfolio including DEFINITY® and TechneLite®.
- Strong position as a leader in imaging diagnostics and therapeutics.
- None.
Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH) today announced that it will host a conference call and webcast at 8:00 a.m. ET on Tuesday, May 4, 2021, to discuss its financial and operating results for the first quarter of 2021.
To access the live conference call via telephone, please dial 1-866-498-8390 (U.S. callers) or 1‑678-509-7599 (international callers) and provide passcode 9275247. A live webcast will also be available in the Investors section of the Company’s website at www.lantheus.com.
A replay of the webcast will be available in the Investors section of the Company’s website approximately two hours after completion of the call and will be archived for 30 days.
About Lantheus Holdings, Inc.
Lantheus Holdings, Inc. is the parent company of Lantheus Medical Imaging, Inc., Progenics Pharmaceuticals, Inc. and EXINI Diagnostics AB and an established leader and fully integrated provider of innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions to Find Fight and Follow® serious medical conditions. Lantheus provides a broad portfolio of products, including the echocardiography agent DEFINITY® Vial for (Perflutren Lipid Microsphere) Injectable Suspension; TechneLite® (Technetium Tc99m Generator), a technetium-based generator that provides the essential medical isotope used in nuclear medicine procedures; AZEDRA® for the treatment of certain rare neuroendocrine tumors; and RELISTOR® for the treatment of opioid-induced constipation, which is partnered with Bausch Health Companies, Inc. The Company is headquartered in North Billerica, Massachusetts with offices in New York, New Jersey, Canada and Sweden. For more information, visit www.lantheus.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210420005150/en/
FAQ
When is the Lantheus Holdings conference call for Q1 2021 results?
How can I access the Lantheus conference call?
What is Lantheus Holdings known for?
Where is Lantheus Holdings headquartered?
